AUS
NZ
UK
CA
USA
IND
Highlights
- LTR Pharma’s nasal spray shows a 470% faster absorption rate.
- The product boasts higher bioavailability compared to oral tablets.
- No adverse effects were reported in clinical trials.
LTR Pharma (ASX:LTP) has revealed promising final study results for its innovative nasal spray SPONTAN, which offers a faster and more effective treatment alternative. According to the findings, SPONTAN is absorbed 470% faster than traditional oral tablets, marking a significant advancement in the treatment of erectile dysfunction.
The unique nasal delivery system used by SPONTAN allows for much quicker absorption into the bloodstream, providing users with a more efficient option compared to the slower-acting oral solutions currently available. In many cases, oral medications can take around forty minutes to become effective, a timeframe that SPONTAN drastically reduces. This faster action gives the product a distinct advantage, offering users a more immediate response.
One of the key factors contributing to this improved performance is the higher bioavailability of SPONTAN. Bioavailability refers to the amount of drug that enters the bloodstream and becomes active in the body. Compared to oral tablets, which lose some of their potency during digestion, SPONTAN’s nasal spray method ensures more of the drug is absorbed directly. This enhances its overall effectiveness, delivering results in less time.
In addition to its faster absorption, LTR Pharma’s SPONTAN was found to be well tolerated during the study. No adverse effects were reported, and the company has underscored that the safety profile of SPONTAN is comparable to that of oral medications. This reinforces the appeal of the product, offering a safe and effective solution for those seeking an alternative to traditional treatments.
According to LTP’s Chief Medical Officer, Prof. Geoffrey Strange, SPONTAN has the potential to address unmet needs in erectile dysfunction treatment due to its rapid onset and favorable pharmacokinetic profile. The ability to deliver quick results, combined with its excellent bioavailability, positions the nasal spray as a more spontaneous and convenient option for those who may not want to wait the extended period required by other oral medications.
LTR Pharma’s focus on creating a superior product has garnered attention, as evidenced by the data supporting SPONTAN’s performance advantages. The combination of faster absorption, higher bioavailability, and a strong safety record makes SPONTAN a product to watch in the pharmaceutical space.
LTR Pharma's stock last traded at $1.93 per share, reflecting growing interest in its innovative approach to addressing key challenges in the market. With its nasal spray solution, LTR Pharma is positioned to provide users with a more convenient and effective treatment experience.
